Upregulation of TGF-ß1 in experimental proliferative vitreoretinopathy is accompanied by epithelial to mesenchymal transition

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 1, 2014, Pages 11-16

  Hoerster, Robert ^a   Muether, Philipp S ^a   Vierkotten, Sarah ^a   Hermann, Manuel M ^a   Kirchhof, Bernd ^a   Fauser, Sascha ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Animal model; Epithelial to mesenchymal transition; Proliferative vitreoretinopathy; TGF

Indexed keywords

COLLAGEN FIBER; EOSIN; HEMATOXYLIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL RETINOPATHY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PIGMENT CELL; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN PURIFICATION; RABBIT; RETINAL THICKNESS; UPREGULATION; VITREORETINOPATHY; WESTERN BLOTTING;

ANIMALS; AQUEOUS HUMOR; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; IMMUNOENZYME TECHNIQUES; RABBITS; RETINAL PIGMENT EPITHELIUM; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; VIMENTIN; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 84892674489     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2377-5     Document Type: Article

References (14)

1. (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90: 121-125
2. Pastor JC (1998) Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 43:3-18
3. Guidry C (2005) The role of Muller cells in fibrocontractive retinal disorders. Prog Retin Eye Res 24:75-86. doi: 10.1016/j.preteyeres.2004.07.001
4. Glaser BM, Cardin A, Biscoe B (1987) Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology 94:327-332
5. Lee H, O'Meara SJ, O'Brien C, Kane R (2007) The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 48:4291-4299
6. Parapuram SK, Chang B, Li L, Hartung RA, Chalam KV, Nair-Menon JU, Hunt DM, Hunt RC (2009) Differential effects of TGFbeta and vitreous on the transformation of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 50:5965-5974
7. Gamulescu MA, Chen Y, He S, Spee C, Jin M, Ryan SJ, Hinton DR (2006) Transforming growth factor beta2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor. Exp Eye Res 83:212-222
8. Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, Mochizuki Y, Enaida H, Goto Y, Shimokawa H, Hafezi-Moghadam A, Ishibashi T (2008) Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 105:17504-17509
9. Lee J, Ko M, Joo C (2008) Rho plays a key role in TGF-beta1-induced cytoskeletal rearrangement in human retinal pigment epithelium. J Cell Physiol 216:520-526
10. Shah M, Foreman DM, Ferguson MW (1994) Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 107(Pt 5):1137-1157
11. Shah M, Foreman DM, Ferguson MW (1995) Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 108(Pt 3):985-1002
12. Campochiaro PA, Gaskin HC, Vinores SA (1987) Retinal cryopexy stimulates traction retinal detachment formation in the presence of an ocular wound. Arch Ophthalmol 105:1567-1570
13. Nassar K, Luke J, Luke M, Kamal M, Abd El-Nabi E, Soliman M, Rohrbach M, Grisanti S (2011) The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch Clin Exp Ophthalmol 249:1649-1660. DOI 10.1007/s00417-011-1730-1739
14. Nassar K, Tura A, Lueke J, Lueke M, Grisanti S (2012) The novel use of LY364947 (LY), a TGF-ß Type I receptor inhibitor, in prevention of proliferative vitreoretinopathy (PVR). Invest Ophthalmol Vis Sci: E-abstract 893